Tiller

Tiller Therapeutics is a clinical-stage biotechnology company specializing in the development of Small Molecule Drug Conjugates (SMDCs) for the treatment of solid tumors. Established in 2024 as a strategic collaboration between Sun Pharma Advanced Research Company (SPARC) and the University of California, San Francisco (UCSF), the company leverages proprietary intellectual property to target high-unmet-need cancers. Its lead candidate, SCO-155 (also known as TILR-097), is currently undergoing IND-enabling studies with an initial focus on metastatic pancreatic cancer. Tiller is led by CEO Eileen McCullough and benefits from a majority equity investment and technical partnership with SPARC. The company's platform aims to deliver potent therapeutic payloads directly to tumor cells while minimizing systemic toxicity.